Corporate News Update – 23 October 2026
Betta L (300558.SZ)
- Trading performance: The stock closed flat, showing a 0 % change during the 24‑hour period ending 09:33 AM Central Europe time on Friday 23 October 2026.
- Current price: CNY 42.57.
- Shares outstanding: 435.6 million.
- Market capitalization: CNY 17.7 billion.
- Trading volume: Approximately CNY 266.8 million of Betta L shares were traded during the last 24 hours.
- Month‑end performance: The share price fell 19.36 % since the end of last month.
- Technical indicator: The 200‑day simple moving average stands at CNY 54.56.
- 52‑week range: The highest price reached CNY 78.18 on 7 June 2026; the lowest price was CNY 38.20 on 20 October 2026.
Related Stock Performances (24‑Hour Period)
| Company | Ticker | % Change | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|---|
| Sichuan Qiaoyuan Gas Ltd | 301286.SZ | 0 % | CNY 50.80 | CNY 21.1 bn | 69.34 |
| Shandong Dongyue Silicone | 300821.SZ | 0 % | CNY 16.23 | CNY 21.1 bn | 49.70 |
| Zhejiang Lante Optics Ltd | 688127.SS | 0 % | CNY 49.92 | CNY 20.8 bn | 52.13 |
| Ningxia Baofeng Energy Group | 600989.SS | 0 % | CNY 21.31 | CNY 22.4 bn | 9.61 |
| Guangdong Zhongsheng Pharma | 002317.SZ | 0 % | CNY 25.96 | CNY 22.8 bn | 111.73 |
Guangdong Zhongsheng Pharma – Regulatory Update
Guangdong Zhongsheng Pharma announced that its wholly‑owned subsidiary, Guangdong Xianqiang Pharmaceutical, has obtained approval from the National Medical Products Administration to list a new chemical raw material, arginine ibuprofen. The approval enables the company to advance its pipeline of pain‑relief and anti‑inflammatory formulations, reflecting its strategic focus on expanding therapeutic offerings within the competitive pharmaceutical market.
About Betta L
Bet Pharmaceuticals Co., Ltd is a Chinese healthcare company listed on the Shenzhen Stock Exchange. The firm specializes in the research, development, manufacturing, sale, and marketing of drugs for malignant tumors, diabetes, cardiovascular, and cerebrovascular diseases. Key products and collaborations include:
- Icotinib hydrochloride – an orally administered, reversible tyrosine kinase inhibitor for non‑small‑cell lung cancer.
- Commercialization partnership with Amgen Inc. for Vectibix in China.
- Collaboration agreement with InventisBio Inc.
Founded in 2003 and headquartered in Hangzhou, the company maintains its corporate website at www.bettapharma.com .
